RetraLabsAU

Atrial natriuretic peptide (ANP)

Also known as: atriopeptin · carperitide

PeptideApproved somewhere28 residuesCardiovascular & renal signalling

A 28-residue peptide released from atrial myocytes in response to stretch, central to the regulation of sodium and fluid balance.

Development status: Approved as a medicine in one or more jurisdictions

Identifiers and molecular characteristics

CAS number
Not verified
Molecular formula
Not verified
Molecular mass
Not verified
Amino-acid sequence
Not verified
PubChem CID
Not verified

Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.

Biological targets

  • NPR-A

Mechanism of action

Raises cGMP via NPR-A, producing natriuresis, diuresis and vasodilation, and opposing the renin–angiotensin–aldosterone system.

Research evidence and its limits

Core cardiovascular physiology. A recombinant form has been approved in some jurisdictions.

Safety considerations

Where this compound is an approved medicine, the authoritative safety source is the product labelling issued by the relevant regulator — not this page. Research-grade material is not pharmaceutical product and carries none of those assurances. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.

Analytical identification and quality testing

Identity by high-resolution mass spectrometry against the expected mass, purity by RP-HPLC with UV detection. Tandem MS sequencing or peptide mapping gives stronger identity evidence than mass alone.

Regulatory status

A recombinant form holds approval in Japan. Status differs by jurisdiction.

References

Related compounds

B-type natriuretic peptide (BNP)

A cardiac natriuretic peptide released in response to ventricular wall stress. Principally important clinically as a diagnostic biomarker rather than as a therapeutic.

Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.